Global Antibody Drug Conjugate Market Size Study, by Mechanism of Action, by Drugs, by Technology, by Indication, by End User and Regional Forecasts 2022-2032

Description

Global Antibody Drug Conjugate Market is valued at approximately USD 5.60 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.12% over the forecast period 2024-2030. The Antibody Drug Conjugate (ADC) Market involves the development, manufacturing, and commercialization of therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissues. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs. However, the complexity of the manufacturing process for ADCs is challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.

The ADC market is experiencing a significant shift towards ErbB2 antibodies (HER2) due to their effectiveness in treating breast and gastric cancer. These ADCs have shown substantial clinical success in targeting the HER2 antigen, which is overexpressed in these cancers. Drugs like Enhertu have become prominent in the oncology field for their targeted therapies, providing improved patient outcomes. The preference for ErbB2 antibodies underscores the market's focus on precision medicine and targeted treatment approaches.

Technological advancements are also shaping the ADC market, with a rising preference for linkerless technology. This technology simplifies the manufacturing process and improves the stability and homogeneity of ADCs. Linkerless ADCs directly conjugate the cytotoxic drug to the antibody, offering streamlined production and potentially enhanced therapeutic efficacy. Additionally, cleavable and non-cleavable linkers continue to play crucial roles, with each offering unique benefits in terms of stability and targeted drug release.

In terms of indications, ADCs are rapidly gaining traction for treating breast cancer. Their ability to target overexpressed receptors, such as HER2, makes them highly effective in managing this prevalent cancer type. Furthermore, ADCs are extensively used for blood cancers, lymphomas, and multiple myeloma, demonstrating their versatility in oncology. These targeted therapies are revolutionizing cancer treatment, providing new hope for patients with previously limited options.

The end-user segment for ADCs is diverse, with significant adoption in academic research institutes, biopharmaceutical and biotechnology companies, hospitals, and specialized cancer centers. Academic research institutes are essential in advancing the understanding of ADC mechanisms and exploring new therapeutic applications. Biopharmaceutical and biotechnology companies are at the forefront of ADC development, investing heavily in R&D to discover novel targets and improve drug-linker technologies. Hospitals and specialized cancer centers play pivotal roles in validating ADC efficacy through clinical trials and integrating these innovative therapies into clinical practice.

The key regions considered for the global Antibody Drug Conjugate Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Antibody Drug Conjugate Market in terms of revenue. The market growth in the region is being attributed to factors including advancements in oncology and targeted therapies. The European Union (EU) maintains a robust regulatory framework for ADCs, fostering strategic collaborations and novel therapy developments. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising R&D expenditure and the prevalence of cancer are propelling the need for ADCs. Additionally, the adoption of advanced technologies for manufacturing ADCs is anticipated to drive their utilization across end-use sectors.

Major market player included in this report are:

AbbVie Inc.
AstraZeneca PLC
Pfizer, Inc.
Roche Holding AG
GlaxoSmithKline PLC
Daiichi Sankyo Company, Limited
Seagen Inc.
ADC Therapeutics SA
ImmunoGen, Inc.
Astellas Pharma Inc.
Bayer AG
Takeda Pharmaceutical Company Limited
Sanofi S.A.
Sorrento Therapeutics, Inc.
BioNTech SE

The detailed segments and sub-segment of the market are explained below:

By Mechanism of Action

CD30 Antibodies
ErbB2 Antibodies

By Drugs

Adcetris
Blenrep
Enhertu
Kadcyla
Padcev
Trodelvy

By Technology

Cleavable Linker
Linkerless
Non-Cleavable Linker

By Indication

Blood Cancer
Breast Cancer
Lymphoma
Multiple Myeloma
Urothelial Cancer & Bladder Cancer

By End User

Academic Research Institutes
Biopharmaceutical & Biotechnology Companies
Hospitals
Specialized Cancer Centers

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Antibody Drug Conjugate Market Executive Summary

1.1. Global Antibody Drug Conjugate Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Mechanism of Action
- 1.3.2. By Drugs
- 1.3.3. By Technology
- 1.3.4. By Indication
- 1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Antibody Drug Conjugate Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Antibody Drug Conjugate Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing Cancer Prevalence
- 3.1.2. Advancements in ADC Technologies
- 3.1.3. Expanding Applications Beyond Oncology
3.2. Market Challenges
- 3.2.1. Complexity of Manufacturing Process
- 3.2.2. High Costs and Regulatory Hurdles
3.3. Market Opportunities
- 3.3.1. Development of Eco-friendly Drugs
- 3.3.2. Technological Advancements in Manufacturing
- 3.3.3. Expansion in Emerging Markets

Chapter 4. Global Antibody Drug Conjugate Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Antibody Drug Conjugate Market Size & Forecasts by Mechanism of Action 2022-2032

5.1. Segment Dashboard
5.2. Global Antibody Drug Conjugate Market: Mechanism of Action Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. CD30 Antibodies
- 5.2.2. ErbB2 Antibodies

Chapter 6. Global Antibody Drug Conjugate Market Size & Forecasts by Drugs 2022-2032

6.1. Segment Dashboard
6.2. Global Antibody Drug Conjugate Market: Drugs Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Adcetris
- 6.2.2. Blenrep
- 6.2.3. Enhertu
- 6.2.4. Kadcyla
- 6.2.5. Padcev
- 6.2.6. Trodelvy

Chapter 7. Global Antibody Drug Conjugate Market Size & Forecasts by Technology 2022-2032

7.1. Segment Dashboard
7.2. Global Antibody Drug Conjugate Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Cleavable Linker
- 7.2.2. Linkerless
- 7.2.3. Non-Cleavable Linker

Chapter 8. Global Antibody Drug Conjugate Market Size & Forecasts by Indication 2022-2032

8.1. Segment Dashboard
8.2. Global Antibody Drug Conjugate Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Blood Cancer
- 8.2.2. Breast Cancer
- 8.2.3. Lymphoma
- 8.2.4. Multiple Myeloma
- 8.2.5. Urothelial Cancer & Bladder Cancer

Chapter 9. Global Antibody Drug Conjugate Market Size & Forecasts by End User 2022-2032

9.1. Segment Dashboard
9.2. Global Antibody Drug Conjugate Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 9.2.1. Academic Research Institutes
- 9.2.2. Biopharmaceutical & Biotechnology Companies
- 9.2.3. Hospitals
- 9.2.4. Specialized Cancer Centers

Chapter 10. Global Antibody Drug Conjugate Market Size & Forecasts by Region 2022-2032

10.1. North America Antibody Drug Conjugate Market
- 10.1.1. U.S. Antibody Drug Conjugate Market
  - 10.1.1.1. Mechanism of Action breakdown size & forecasts, 2022-2032
  - 10.1.1.2. Drugs breakdown size & forecasts, 2022-2032
  - 10.1.1.3. Technology breakdown size & forecasts, 2022-2032
  - 10.1.1.4. Indication breakdown size & forecasts, 2022-2032
  - 10.1.1.5. End User breakdown size & forecasts, 2022-2032
- 10.1.2. Canada Antibody Drug Conjugate Market
  - 10.1.2.1. Mechanism of Action breakdown size & forecasts, 2022-2032
  - 10.1.2.2. Drugs breakdown size & forecasts, 2022-2032
  - 10.1.2.3. Technology breakdown size & forecasts, 2022-2032
  - 10.1.2.4. Indication breakdown size & forecasts, 2022-2032
  - 10.1.2.5. End User breakdown size & forecasts, 2022-2032
10.2. Europe Antibody Drug Conjugate Market
- 10.2.1. U.K. Antibody Drug Conjugate Market
  - 10.2.1.1. Mechanism of Action breakdown size & forecasts, 2022-2032
  - 10.2.1.2. Drugs breakdown size & forecasts, 2022-2032
  - 10.2.1.3. Technology breakdown size & forecasts, 2022-2032
  - 10.2.1.4. Indication breakdown size & forecasts, 2022-2032
  - 10.2.1.5. End User breakdown size & forecasts, 2022-2032
- 10.2.2. Germany Antibody Drug Conjugate Market
- 10.2.3. France Antibody Drug Conjugate Market
- 10.2.4. Spain Antibody Drug Conjugate Market
- 10.2.5. Italy Antibody Drug Conjugate Market
- 10.2.6. Rest of Europe Antibody Drug Conjugate Market
10.3. Asia-Pacific Antibody Drug Conjugate Market
- 10.3.1. China Antibody Drug Conjugate Market
- 10.3.2. India Antibody Drug Conjugate Market
- 10.3.3. Japan Antibody Drug Conjugate Market
- 10.3.4. Australia Antibody Drug Conjugate Market
- 10.3.5. South Korea Antibody Drug Conjugate Market
- 10.3.6. Rest of Asia Pacific Antibody Drug Conjugate Market
10.4. Latin America Antibody Drug Conjugate Market
- 10.4.1. Brazil Antibody Drug Conjugate Market
- 10.4.2. Mexico Antibody Drug Conjugate Market
- 10.4.3. Rest of Latin America Antibody Drug Conjugate Market
10.5. Middle East & Africa Antibody Drug Conjugate Market
- 10.5.1. Saudi Arabia Antibody Drug Conjugate Market
- 10.5.2. South Africa Antibody Drug Conjugate Market
- 10.5.3. Rest of Middle East & Africa Antibody Drug Conjugate Market

Chapter 11. Competitive Intelligence

11.1. Key Company SWOT Analysis
11.2. Top Market Strategies
11.3. Company Profiles
- 11.3.1. Roche Holding AG
  - 11.3.1.1. Key Information
  - 11.3.1.2. Overview
  - 11.3.1.3. Financial (Subject to Data Availability)
  - 11.3.1.4. Product Summary
  - 11.3.1.5. Market Strategies
- 11.3.2. GlaxoSmithKline PLC
- 11.3.3. Daiichi Sankyo Company, Limited
- 11.3.4. Seagen Inc.
- 11.3.5. ADC Therapeutics SA
- 11.3.6. ImmunoGen, Inc.
- 11.3.7. Astellas Pharma Inc.
- 11.3.8. Bayer AG
- 11.3.9. Takeda Pharmaceutical Company Limited
- 11.3.10. Sanofi S.A.
- 11.3.11. Sorrento Therapeutics, Inc.
- 11.3.12. BioNTech SE
- 11.3.13. AbbVie Inc.
- 11.3.14. AstraZeneca PLC
- 11.3.15. Pfizer, Inc.

Chapter 12. Research Process

12.1. Research Process
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation
- 12.1.5. Publishing
12.2. Research Attributes